Akt and p53R2, partners that dictate the progression and invasiveness of cancer.

Akt and p53R2, partners that dictate the progression and invasiveness of cancer.

Item
http://www.wikidata.org/entity/Q38236284
Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews.The Succinate Receptor GPR91 Is Involved in Pressure Overload-Induced Ventricular Hypertrophy.5-aza-2',2'-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of CancerPeroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies.Breast tumor stroma: A driving force in the development of resistance to therapies.New insights into antidiabetic drugs: Possible applications in cancer treatment.Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.Chronic type-I diabetes could not impede the anti-inflammatory and anti-apoptotic effects of combined postconditioning with ischemia and cyclosporine A in myocardial reperfusion injury.p53R2 is oncogenic in human cervical cancer.
P2860

Akt and p53R2, partners that dictate the progression and invasiveness of cancer.

Item
http://www.wikidata.org/entity/Q38236284
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Akt and p53R2, partners that dictate the progression and invasiveness of cancer.
@en
type
label
Akt and p53R2, partners that dictate the progression and invasiveness of cancer.
@en
prefLabel
Akt and p53R2, partners that dictate the progression and invasiveness of cancer.
@en
P1433
P1476
P2093
P304
P31
P356
P478
P50
P577
P5875
P698
P356
P1433
P1476
Akt and p53R2, partners that dictate the progression and invasiveness of cancer.
@en
P2093
P304
P31
P356
10.1016/J.DNAREP.2014.07.001
P478
P50
P577
P5875
P698